# A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

> **NCT04734262** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 98 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Sitravatinib
- **DRUG:** Tislelizumab
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT04734262
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04734262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04734262, "A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04734262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*